NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Krispy Kreme, Inc. (NASDAQ:DNUT), Digimarc Corporation (NASDAQ:DMRC), Elevance Health, Inc. (NYSE:ELV), and Iovance Biotherapeutics, Inc. (NASDAQ:IOVA). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Krispy Kreme, Inc. (NASDAQ: DNUT)
Class Period: February 25, 2025 - May 7, 2025
Lead Plaintiff Deadline: July 15, 2025
Krispy Kreme, together with its subsidiaries, produces doughnuts. On October 26, 2022, Krispy Kreme commenced a small-scale test to offer doughnuts at McDonald's Corporation restaurants in Louisville, Kentucky and the surrounding area and on March 26, 2024, Krispy Kreme and McDonald's announced they would expand their partnership nationwide beginning in the second half of 2024, the complaint alleges.
The Krispy Kreme class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) demand for Krispy Kreme products declined materially at McDonald's locations after the initial marketing launch; (ii) demand at McDonald's locations was a driver of declining average sales per door per week; (iii) the partnership with McDonald's was not profitable; (iv) the foregoing posed a substantial risk to maintaining the partnership with McDonald's; and (v) as a result, Krispy Kreme would pause expansion into new McDonald's locations.
The Krispy Kreme class action lawsuit further alleges that on May 8, 2025, Krispy Kreme released its first quarter 2025 financial results, reporting its "[n]et revenue was $375.2 million . . . a decline of 15.3%" and a "[n]et [l]oss [of] $33.4 million, compared to prior year net loss of $6.7 million." Additionally, Krispy Kreme announced that it is "reassessing [its] deployment schedule together with McDonald's" and "withdrawing its prior full year outlook and not updating it" due in part to "uncertainty around the McDonald's deployment schedule," the complaint alleges. On this news, the price of Krispy Kreme shares fell by nearly 25%, the Krispy Kreme class action lawsuit alleges.
For more information on the Krispy Kreme class action go to: https://bespc.com/cases/DNUT
Digimarc Corporation (NASDAQ:DMRC)
Class Period: May 3, 2024 - February 26, 2025
Lead Plaintiff Deadline: July 7, 2025
According to the Complaint, the Company made false and misleading statements to the market. A large commercial partner of Digimarc would not renew its contract on the same terms. As a result, the Company would renegotiate the large commercial contract. Based on this renegotiation, the Company’s subscription revenue and annual recurring revenue would be adversely affected. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Digimarc, investors suffered damages.
For more information on the Digimarc class action go to: https://bespc.com/cases/DMRC
Elevance Health, Inc. (NYSE:ELV)
Class Period: April 18, 2024, and October 16, 2024
Lead Plaintiff Deadline: July 11, 2025
According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that, with the Medicaid redetermination process nearly complete, defendants represented to investors that they were closely monitoring cost trends associated with the redetermination process and that the premium rates Elevance was negotiating with states were sufficient to address the risk and cost profiles of those patients staying on Medicaid programs. While defendants acknowledged that Medicaid expenses were rising, they repeatedly assured investors that this was adequately reflected in Elevance’s guidance for the year. These representations were materially false or misleading. In truth, the redeterminations were causing the acuity and utilization of Elevance’s Medicaid members to rise significantly, as the members being removed from Medicaid programs were, on average, healthier than those who remained eligible for the programs. This shift was occurring to a degree that was not reflected in Elevance’s rate negotiations with the states or in its financial guidance for 2024. When the true details entered the market, the lawsuit claims that investors suffered damages.
For more information on the Elevance class action go to: https://bespc.com/cases/ELV
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Class Period: May 9, 2024 - May 8, 2025
Lead Plaintiff Deadline: July 14, 2025
According to the complaint, throughout the class period, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Iovance's growth potential; notably, that it was not equipped to generate and drive demand or was otherwise ill equipped to capitalize upon the purported existing demand for its treatments through its network of approved treatment centers.
On July 25, 2024, Iovance announced its financial results for the second quarter of fiscal 2024 and reduced its revenue guidance for the full fiscal year 2024. The Company attributed its results and lowered guidance on 1) "the iCTC completed annual scheduled maintenance in December" and "capacity was reduced by more than half for about 1 month," 2) "[l]ower Proleukin sales" than the company expected, and 3) "the variable pace at which ATCs began treatment patients."
Following this news, the price of Iovance's common stock declined dramatically. From a closing market price of $3.17 per share on May 8, 2025, Iovance's stock price fell to $1.75 per share on May 9, 2025, a decline of about 44.795% in the span of just a single day.
For more information on the Iovance class action go to: https://bespc.com/cases/IOVA
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com
